Neurocrine Bioscience Sees Relative Strength Rating Jump
Neurocrine Biosciences (NBIX) cleared a benchmark Wednesday. The Relative Strength Rating for Neurocrine jumped from 77 to 82. Some technical analysts see a Relative Strength Rating of 80 or higher as a buy signal. Investors' Business. Continue reading